PharmEasy logs first EBITDA profit of Rs 14 crore in April, and restarts funding talks PharmEasy, an online pharmacy startup, has announced that it has registered its first month of positive EBITDA in April. This marks a significant milestone for the company, which has been working towards profitability since it was founded in 2015.
![The EBITDA profit of Rs 14 crore was achieved by PharmEasy in April, a month that saw the market grow significantly due to the lockdown imposed as a result of the CO](https://bharatinvest.com/wp-content/uploads/2023/05/Unknown-3.png)
In addition to this, the company has also restarted talks with potential investors for a new round of funding. This is a positive development for the company, which had been struggling to raise capital in recent months.
This news is a positive sign for the Indian startup ecosystem, which has been hit hard by the Covid-19 pandemic. It shows that there is still potential for growth and investment
In addition to this, the company has also restarted talks with potential investors for a new round of funding. This is a positive development for the company, which had been struggling to raise capital in recent months.
This news is a positive sign for the Indian startup ecosystem, which has been hit hard by the Covid-19 pandemic. It shows that there is still potential for growth and investment in the sector, despite the challenges that have been faced in recent months.
The company’s decision to restart talks with potential investors is a welcome development and is likely to bring much-needed capital into the sector. This will help to bolster the Indian startup ecosystem and could lead to further growth and investment in the sector investment in the sector, despite the challenges that have been faced in recent months.
The COVID-19 pandemic has caused significant disruption to the Indian economy, with many startups struggling to survive. However, the potential infusion of capital from new investors could provide a much-needed lifeline for many of these firms, helping them to weather the storm and continue to innovate and expand.
Pharmeasy is India’s leading online pharmacy and has been operational for over 5 years. The company has been growing rapidly and has now raised over $200 million in funding from top tier investors.
Pharmeasy is not listed on any stock exchange but investors can still buy shares in the company through the secondary market. Shares of Pharmeasy are not easy to come by but they can be found on some of the leading online marketplaces like BSE and NSE.
If you’re looking to invest in Pharmeasy, we highly recommend doing so through the secondary market. This will give you the ability to get in on the ground floor of one of India’s leading online pharmacies.